212 related articles for article (PubMed ID: 29177891)
1. Plasma levels of hypoxia-regulated factors in patients with age-related macular degeneration.
Ioanna Z; Christian S; Christian G; Daniel B
Graefes Arch Clin Exp Ophthalmol; 2018 Feb; 256(2):325-332. PubMed ID: 29177891
[TBL] [Abstract][Full Text] [Related]
2. PEDF and VEGF plasma level alterations in patients with dry form of age-related degeneration--a possible link to the development of the disease.
Machalińska A; Safranow K; Mozolewska-Piotrowska K; Dziedziejko V; Karczewicz D
Klin Oczna; 2012; 114(2):115-20. PubMed ID: 23346798
[TBL] [Abstract][Full Text] [Related]
3. Imbalanced levels of angiogenic and angiostatic factors in vitreous, plasma and postmortem retinal tissue of patients with proliferative diabetic retinopathy.
Mohan N; Monickaraj F; Balasubramanyam M; Rema M; Mohan V
J Diabetes Complications; 2012; 26(5):435-41. PubMed ID: 22699109
[TBL] [Abstract][Full Text] [Related]
4. Intraocular Vascular Endothelial Growth Factor Levels in Pachychoroid Neovasculopathy and Neovascular Age-Related Macular Degeneration.
Hata M; Yamashiro K; Ooto S; Oishi A; Tamura H; Miyata M; Ueda-Arakawa N; Takahashi A; Tsujikawa A; Yoshimura N
Invest Ophthalmol Vis Sci; 2017 Jan; 58(1):292-298. PubMed ID: 28114590
[TBL] [Abstract][Full Text] [Related]
5. Intraocular and systemic inflammation-related cytokines during one year of ranibizumab treatment for neovascular age-related macular degeneration.
Fauser S; Viebahn U; Muether PS
Acta Ophthalmol; 2015 Dec; 93(8):734-8. PubMed ID: 26016605
[TBL] [Abstract][Full Text] [Related]
6. Vitreous and aqueous concentrations of proangiogenic, antiangiogenic factors and other cytokines in diabetic retinopathy patients with macular edema: Implications for structural differences in macular profiles.
Patel JI; Tombran-Tink J; Hykin PG; Gregor ZJ; Cree IA
Exp Eye Res; 2006 May; 82(5):798-806. PubMed ID: 16324700
[TBL] [Abstract][Full Text] [Related]
7. PLASMA CONCENTRATIONS OF VASCULAR ENDOTHELIAL GROWTH FACTOR IN RETINOPATHY OF PREMATURITY AFTER INTRAVITREAL BEVACIZUMAB INJECTION.
Hong YR; Kim YH; Kim SY; Nam GY; Cheon HJ; Lee SJ
Retina; 2015 Sep; 35(9):1772-7. PubMed ID: 25829347
[TBL] [Abstract][Full Text] [Related]
8. The Proteomic Landscape in the Vitreous of Patients With Age-Related and Diabetic Retinal Disease.
Schori C; Trachsel C; Grossmann J; Zygoula I; Barthelmes D; Grimm C
Invest Ophthalmol Vis Sci; 2018 Mar; 59(4):AMD31-AMD40. PubMed ID: 30025106
[TBL] [Abstract][Full Text] [Related]
9. Pigment epithelium-derived factor is deficient in the vitreous of patients with choroidal neovascularization due to age-related macular degeneration.
Holekamp NM; Bouck N; Volpert O
Am J Ophthalmol; 2002 Aug; 134(2):220-7. PubMed ID: 12140029
[TBL] [Abstract][Full Text] [Related]
10. Changes in aqueous vascular endothelial growth factor and pigment epithelium-derived factor after ranibizumab alone or combined with verteporfin for exudative age-related macular degeneration.
Ahn JK; Moon HJ
Am J Ophthalmol; 2009 Nov; 148(5):718-724.e1. PubMed ID: 19674731
[TBL] [Abstract][Full Text] [Related]
11. Plasma levels of vascular endothelial growth factor and pigment epithelium-derived factor before and after intravitreal injection of bevacizumab.
Matsuyama K; Ogata N; Matsuoka M; Wada M; Takahashi K; Nishimura T
Br J Ophthalmol; 2010 Sep; 94(9):1215-8. PubMed ID: 20538658
[TBL] [Abstract][Full Text] [Related]
12. Correlation between ficolin-3 and vascular endothelial growth factor-to-pigment epithelium-derived factor ratio in the vitreous of eyes with proliferative diabetic retinopathy.
Zheng B; Li T; Chen H; Xu X; Zheng Z
Am J Ophthalmol; 2011 Dec; 152(6):1039-43. PubMed ID: 21851923
[TBL] [Abstract][Full Text] [Related]
13. Aqueous humor levels of vascular endothelial growth factor and pigment epithelium-derived factor in polypoidal choroidal vasculopathy and choroidal neovascularization.
Tong JP; Chan WM; Liu DT; Lai TY; Choy KW; Pang CP; Lam DS
Am J Ophthalmol; 2006 Mar; 141(3):456-62. PubMed ID: 16490490
[TBL] [Abstract][Full Text] [Related]
14. Role of soluble vascular endothelial growth factor receptor-1 in the vitreous in proliferative diabetic retinopathy.
Matsunaga N; Chikaraishi Y; Izuta H; Ogata N; Shimazawa M; Matsumura M; Hara H
Ophthalmology; 2008 Nov; 115(11):1916-22. PubMed ID: 18718666
[TBL] [Abstract][Full Text] [Related]
15. Clinical Significance of Serum Vascular Endothelial Growth Factor, Pigment Epithelium-Derived Factor, Tumor Necrosis Factor Alpha, and Progranulin Levels in Patients with Gastric Cancer and Gastric Precancerous Lesions.
Aksoy EK; Akpınar MY; Doğan Ö; Göktaş Z; Sapmaz FP; Şimşek GG; Uzman M; Nazlıgül Y
J Gastrointest Cancer; 2019 Sep; 50(3):537-542. PubMed ID: 31089953
[TBL] [Abstract][Full Text] [Related]
16. Vitreous levels of pigment epithelium-derived factor and vascular endothelial growth factor: implications for ocular angiogenesis.
Duh EJ; Yang HS; Haller JA; De Juan E; Humayun MS; Gehlbach P; Melia M; Pieramici D; Harlan JB; Campochiaro PA; Zack DJ
Am J Ophthalmol; 2004 Apr; 137(4):668-74. PubMed ID: 15059706
[TBL] [Abstract][Full Text] [Related]
17. EPIRETINAL MEMBRANES IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: Effect on Outcomes of Anti-vascular Endothelial Growth Factor Therapy.
Karaca EE; Kepez Yldz B; Çubuk MÖ; Özdek Ş
Retina; 2015 Aug; 35(8):1540-6. PubMed ID: 25768251
[TBL] [Abstract][Full Text] [Related]
18. Aqueous Humor Levels of Cytokines in Patients with Age-Related Macular Degeneration.
Mimura T; Funatsu H; Noma H; Shimura M; Kamei Y; Yoshida M; Kondo A; Watanabe E; Mizota A
Ophthalmologica; 2019; 241(2):81-89. PubMed ID: 30048978
[TBL] [Abstract][Full Text] [Related]
19. Serum and intraocular concentrations of erythropoietin and vascular endothelial growth factor in patients with type 2 diabetes and proliferative retinopathy.
Semeraro F; Cancarini A; Morescalchi F; Romano MR; dell'Omo R; Ruggeri G; Agnifili L; Costagliola C
Diabetes Metab; 2014 Dec; 40(6):445-51. PubMed ID: 24878492
[TBL] [Abstract][Full Text] [Related]
20. Recovery of plasma vascular endothelial growth factor concentrations during aflibercept loading phase and after the transition to bimonthly treatment for neovascular age-related macular degeneration.
Roald AB; Aass HC; Moe MC
Br J Ophthalmol; 2015 Dec; 99(12):1610-3. PubMed ID: 25966740
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
